The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial.
Nai-Jung Chiang
No relevant relationships to disclose
Chiun Hsu
No relevant relationships to disclose
Jen-Shi Chen
No relevant relationships to disclose
Hiso-Hui Tsou
No relevant relationships to disclose
Yee Chao
No relevant relationships to disclose
Yang-Shen Shan
No relevant relationships to disclose
Shiu-Feng Huang
No relevant relationships to disclose
Chang-Fang Chiu
No relevant relationships to disclose
Kuan-Der Lee
No relevant relationships to disclose
Li-Tzong Chen
No relevant relationships to disclose